In Vivo Coinstantaneous Identification of Hepatocellular Carcinoma Circulating Tumor Cells by Dual-Targeting Magnetic-Fluorescent Nanobeads.
Wenxi XiaHaidong LiYueqing LiMiao LiJiangli FanWen SunNa LiRuojie LiKun ShaoXiaojun PengPublished in: Nano letters (2020)
Circulating tumor cells (CTCs) have been considered as a potential biomarker for evaluation of cancer metastasis and prognosis, especially in hepatocellular carcinoma (HCC). However, the isolation and detection of rare CTCs in HCC patients face enormous challenges due to omittance and nonspecific binding. We previously designed a small molecular NIR fluoresent agent, named MLP, which had high affinity with a tumor cell-overexpressed enzyme, aminopeptidase N (APN). Based on that, in this work we introduced a novel strategy via coassembling the antiepithelial cell adhesion molecule (EpCAM) antibody and MLPinto theFe3O4 magnetic nanobeads (MB-MLP-EpCAM) to isolate and identify HCC-CTCs coinstantaneously. MB-MLP-EpCAM significantly improved the CTC-capture efficiency (>85%) without sacrificing cell viability (>90%). Most importantly, the advantages of precise dual-targetability, high resolution of fluorescence imaging, and prominent selectivity make our nanoplatform have great potential to achieve in vivo real-time identification and monitoring of CTCs clinically.
Keyphrases
- circulating tumor cells
- fluorescence imaging
- cell adhesion
- photodynamic therapy
- high resolution
- circulating tumor
- end stage renal disease
- cancer therapy
- newly diagnosed
- ejection fraction
- chronic kidney disease
- molecularly imprinted
- papillary thyroid
- prognostic factors
- mass spectrometry
- squamous cell carcinoma
- label free
- drug release
- stem cells
- single cell
- bioinformatics analysis
- drug delivery
- cell therapy
- squamous cell
- climate change
- living cells
- patient reported outcomes
- binding protein
- lymph node metastasis
- young adults
- human health
- dna binding
- sensitive detection